GLIOMATCH 5th consortium meeting takes place in Barcelona
On 28–29 April 2026, the GLIOMATCH consortium gathered in Barcelona, Spain, for its fifth consortium meeting, hosted by project partner Sant Joan de Déu Barcelona Children’s Hospital and the Fundació de Recerca Sant Joan de Déu (FSJD).
Second annual meeting of the Understanding (tumour-host interactions) Cluster held in Warsaw
GLIOMATCH joined partners of the Understanding (tumour-host interactions) Cluster – an initiative of the EU’s Cancer Mission – in Warsaw in March 2026 to review scientific progress, strengthen collaboration and advance joint work on data management and policy-relevant research.
GLIOMATCH results contribute to new EIC-funded project GLIOBREAK
Results from GLIOMATCH are supporting the newly funded EIC Transition project GLIOBREAK, coordinated by Beactica Therapeutics and with the involvement of KU Leuven. The project will advance BEA-17, a first-in-class LSD1–CoREST degrader, towards clinical readiness, including IND-enabling studies and regulatory submission.
International Childhood Cancer Day 2026
On International Childhood Cancer Day, GLIOMATCH highlights the urgent need for research into paediatric high-grade gliomas (pHGGs), rare and aggressive brain tumours affecting children. With a median survival of just over one year and no curative treatment available, collaborative research efforts are essential to better understand the disease, develop dedicated models, and tailor therapies that improve outcomes and quality of life for young patients and their families.
International Day of Women and Girls in Science 2026
GLIOMATCH celebrates the women researchers across its consortium whose expertise and commitment drive the development of tailored immunotherapies for malignant brain tumours, marking the International Day of Women and Girls in Science 2026.
World Cancer Day 2026
On World Cancer Day 2026, GLIOMATCH highlights the importance of placing patient perspectives at the heart of cancer research, particularly for glioblastoma, one of the most aggressive and difficult-to-treat brain tumours.
GLIOMATCH successfully completes Reporting Period 1
GLIOMATCH has successfully completed its first reporting period (RP1), marking a key milestone in advancing data-driven precision medicine for malignant glioma. A new Results page is now available, providing access to public deliverables and scientific publications.
Discover the Understanding (tumour-host interactions) Cluster projects through our video and brochure
Discover the Understanding (tumour-host interactions) Cluster and its joint work under the EU Cancer Mission through our new brochure and introductory video.
Understanding (tumour-host interactions) Cluster publishes first joint press release!
A new joint press release presents the key outcomes of the first annual meeting of the Understanding (tumour-host interactions) Cluster, held in Barcelona in January 2025. It outlines how cluster partners are strengthening collaboration, advancing data sharing strategies and contributing to policy recommendations to support cancer research and patient outcomes across Europe.
First annual meeting of the Understanding (tumour-host interactions) Cluster held in Barcelona
On 31 January 2025, partners from across the Understanding (tumour-host Interactions) Cluster (U-THI-Clust) gathered in Barcelona, Spain, for the first annual cluster meeting, organised by the THRIVE project at the Centre Esther Koplowitz (IDIBAPS). The meeting brought together representatives from the six cluster projects, namely ARTURO, GLIOMATCH, HIT-GLIO, MULTIR, SPACETIME and THRIVE, alongside the Project Officer from HaDEA.